Nuwellis, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights

Core Insights - Nuwellis, Inc. reported a revenue of $1.7 million for Q2 2025, down from $2.2 million in Q2 2024, primarily due to a product backorder linked to an industry-wide sterilization vendor issue [3][5][7] - The company is focusing on high-impact growth areas in pediatric and cardiac surgery care while preparing for expansion in outpatient heart failure [2][3] - Nuwellis completed a $5 million gross capital raise during the quarter and has a cash position of $4.5 million as of June 30, 2025 [5][7] Financial Performance - Gross margin decreased to 55.5% in Q2 2025 from 67.2% in Q2 2024, attributed to lower production volumes [4] - Operating loss for the quarter was $2.9 million, compared to a loss of $2.3 million in Q2 2024 [5][15] - Net loss attributable to common shareholders was $12.6 million, or a loss of $60.99 per share, compared to a net loss of $7.7 million, or a loss of $791.82 per share in Q2 2024 [5][15] Business Developments - The pediatric category remains a key driver of sustained demand, with 47 pediatric centers adopting Aquadex therapy [7] - The company executed a transition plan to outsource manufacturing to KDI Precision Manufacturing [7] - Nuwellis expanded its intellectual property portfolio with a new U.S. patent covering a fluid bag design that passively drains once full [7]